-
SR-4835
- names:
SR-4835
- CAS号:
2387704-62-1
MDL Number: - MF(分子式): C21H20Cl2N10O MW(分子量): 499.36
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM001126-250mg | 250mg | ¥ 0.00 | ¥ 0.00 | Backorder | ¥ 0.00 | |||
| YZM001126-100mg | 100mg | >97% | ¥ 0.00 | ¥ 0.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 2387704-62-1 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C21H20Cl2N10O |
| 分子量 Molecular Weight | 499.36 |
| 溶解度Solubility | |
| 性状 | |
| 储藏条件 Storage conditions | 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description. |
SR-4835(CAS:2387704-62-1)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | SR-4835 为有效,高选择性和 ATP 竞争性的CDK12/CDK13双重抑制剂 (CDK12:IC50=99 nM,Kd=98 nM;CDK13:Kd=4.9 nM) |
| Introduction | SR835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13(CDK12:IC50=99 nM,Kd=98 nM; CDK13:Kd=4.9 nM). SR835 acts in synergy with DNAamaging chemotherapy and PARP inhibitors and provokes tripleegative breast cancer (TNBC) cell death. |
| Application1 | |
| Application2 | |
| Application3 |
SR-4835 为有效,高选择性和 ATP 竞争性的CDK12/CDK13双重抑制剂 (CDK12:IC50=99 nM,Kd=98 nM;CDK13:Kd=4.9 nM)。SR-4835 与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用,并引起三阴性乳腺癌 (TNBC) 细胞凋亡。SR-4835 is a potent, highly selective and ATP competitive dual inhibitor ofCDK12/CDK13(CDK12:IC50=99 nM,Kd=98 nM; CDK13:Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].
【1】.Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


